EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of polycythemia vera in children

Alexey V. Bogdanov, A. V. Pshonkin, M. V. Gaskova, P. A. Zharkov, A. V. Poletaev, S. A. Lebedeva, O. V. Lotonina, N. S. Smetanina

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 145-153

DOI: 10.24287/j.1132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Alexey V. Bogdanov und 7 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Polycythemia vera (PV) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm that is extremely rare in childhood. Currently, there are no reliable data on the efficacy and tolerability of cytoreductive therapy in children with PV. The aim of the study is to evaluate the clinical and hematological and molecular response, as well as the tolerability of cytoreductive therapy in patients under 18 years of age with PV. Materials and methods. The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology has developed its own management strategy for patients with PV: cytoreductive therapy is administered in the presence of a driver mutation in the JAK2V617F gene, JAK2 exon 12, and/or microcirculatory disorders with von Willebrand factor deficiency, or in the absence of an effect from antiplatelet agents in patients with microcirculatory disorders, or in patients with hemorrhagic syndrome and acquired von Willebrand factor deficiency. A total of 48 patients were included in the study (35 boys and 13 girls). The median follow-up period was 2.3 (2.0–3.7) years. The median age at diagnosis was 14.9 (9.0–16.8) years. The JAK2V617F mutation was found in 30 (62.5%) patients, the JAK2 exon 12 mutation – in 3 (6.25%) patients, and 15 (31.25%) patients were JAK2-negative. Cytoreductive therapy was administered to 28 (58%) patients.

Results

The majority of patients achieved a partial clinical and hematological response in the first year of treatment: 21/25 (84.0%) patients in the group treated with interferon and 7/8 (87.5%) in the group treated with hydroxycarbamide. In the interferon group, a partial molecular response was registered in 12/17 (70.5%) patients; 5/17 (29.5%) patients showed no molecular response. The median JAK2V617F/JAK2 exon 12 allele burden decreased from 24% (17–30%) to 15% (9–22%) (z = 3.5; p 0.001). In the hydroxycarbamide group, the allele burden did not change significantly in any of the 7 (100%) patients (p = 0.916).

Conclusion

Our findings support further investigation of interferons as a preferred cytoreductive treatment option in children and adolescents with PV.

Zitieren

APA

Bogdanov, A. V., Pshonkin, A. V., Gaskova, M. V., Zharkov, P. A., Poletaev, A. V., Lebedeva, S. A., Lotonina, O. V., & Smetanina, N. S. (2026). Treatment of polycythemia vera in children. Pediatric Hematology/Oncology and Immunopathology, 25(2), 145-153. https://doi.org/10.24287/j.1132

Vancouver

Bogdanov AV, Pshonkin AV, Gaskova MV, Zharkov PA, Poletaev AV, Lebedeva SA, et al. Treatment of polycythemia vera in children. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):145-153. doi:10.24287/j.1132

BibTeX
@article{Bogdanov2026,
  author = {Bogdanov, Alexey V. and Pshonkin, A. V. and Gaskova, M. V. and Zharkov, P. A. and Poletaev, A. V. and Lebedeva, S. A. and Lotonina, O. V. and Smetanina, N. S.},
  title = {Treatment of polycythemia vera in children},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {145--153},
  doi = {10.24287/j.1132}
}
Kostenlos starten →